title: A new drug target for treatment of dyslipidaemia associated with type 2 diabetes and the metabolic syndrome?
authors.affiliation: MRC Clinical Sciences Centre, Hammersmith Hospital, London, UK
authors.forename: Rossitza P
authors.initials: RP
authors.lastname: Naoumova
authors.forename: D John
authors.initials: DJ
authors.lastname: Betteridge
mesh_terms: D000091303:Angiopoietin-Like Protein 3; D000075802:Angiopoietin-like Proteins; D042682:Angiopoietins; D000818:Animals; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D006133:Growth Substances / Q000235:genetics / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy; D036341:Intercellular Signaling Peptides and Proteins; D024821:Metabolic Syndrome / Q000235:genetics; D051379:Mice; D008820:Mice, Obese; D014280:Triglycerides / Q000097:blood
chemical_list: D000091303:Angiopoietin-Like Protein 3; D000075802:Angiopoietin-like Proteins; D042682:Angiopoietins; C404495:Angptl3 protein, mouse; D006133:Growth Substances; D036341:Intercellular Signaling Peptides and Proteins; D014280:Triglycerides